ChartMill · Oct 30, 2026
Protagonist Therapeutics (NASDAQ:PTGX) Eyes Breakout as High Growth Momentum Builds
PTGX blends strong technicals (9) and high growth momentum (6) with a Setup Rating of 7, nearing a breakout despite clinical-stage risks.
PT
NASDAQ · PTGX
Protagonist Therapeutics, Inc.
Healthcare · Biotechnology
$139.37
Up+$2.00 (+1.43%)
Updated Nov 3, 2026, 5:49 PM
SID Score
5.1/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 5.77B
- P/E ratio
- 128.14
- Dividend yield
- 0.00%
- 52-week range
- $90.58 – $160.81
- Volume
- 487.07K
- Avg. volume
- 1.18M
Price performance · PTGX
PTGX price history
1M range · 0 trading sessions · Daily adjusted prices
PTGX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest PTGX news
The latest Smart Investors Daily articles mentioning PTGX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PTGX research
Overview
Company profile and research snapshot.
Company profile
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $90.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 21, 2026 | TD Cowen | Buy | — |
| Oct 12, 2026 | UBS | Buy | — |
| Sep 1, 2026 | BMO Capital | Outperform | — |
| Sep 1, 2026 | Barclays | Overweight | — |
| Aug 31, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 29, 2026
Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 28, 2026
Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
The mean of analysts' price targets for Protagonist Therapeutics (PTGX) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Yahoo · Oct 27, 2026
Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026
NEWARK, CA / ACCESS Newswire / October 27, 2026 / (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that senior management will participate in four investment bank conferences taking place in November 2026.8th Annual Wolfe Research Healthcare Conference Format: Fireside Chat and 1x1 meetings Date: Tuesday, November 10, 2026 Time: 1:20 - 1:50 p.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
